GE HealthCare Technologies Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $GEHC in the last 30 days.
See all $GEHC insider activity →GE HealthCare (GEHC) will release its Q3 2026 financial results on October 28, 2026, before market open. The company is a global healthcare provider offering medical tech, diagnostics, and AI solutions. A live call will follow the announcement at 8:30 a.m. ET.
Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Notable upgrades include Marvell (MRVL) to Buy with a $350 target and NetApp (NTAP) to Outperform with a $300 target. Downgrades include AppFolio (APPF) to Neutral with a $220 target. Initiations include Abbott Laboratories (ABT) with an Overweight rating and $120 target. Major indices closed at record highs, with the S&P 500 at 7,818 and Nasdaq at 27,599.
Philips, GE HealthCare, and Siemens Healthineers face lawsuits from MR Access over alleged MRI patent infringements. The patents cover technology for improving MRI scan quality. MR Access, founded by MRI experts, seeks to license its patented technology.
Over the past 7 days, AlphAI's AI scored 27 news stories mentioning GEHC (GE HealthCare Technologies Inc.). Coverage has skewed bullish: 24 bullish, 2 neutral, and 1 bearish.
Recent GEHC coverage spans financial news, technology and mergers & acquisitions.
The upcoming earnings release may trigger short‑term price volatility as traders react to the disclosed numbers.
New Overweight coverage suggests strong upside potential.
Legal exposure may weigh on GE HealthCare's valuation.
Analyst upgrade and a sizable acquisition suggest near‑term upside potential.
Evercore ISI lowered its price target for GE Healthcare Technologies from $84 to $83, while maintaining an Outperform rating. The stock is currently trading at $64.32, reflecting a 0.05% gain over 5 days and a 4.55% decline over 1 year.
AlphAI scores every news story that mentions GEHC with an AI model for sentiment and relevance, and aggregates insider trades from GE HealthCare Technologies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GE HealthCare (GEHC) will release its Q3 2026 financial results on October 28, 2026, before market open. The company is a global healthcare provider offering medical tech, diagnostics, and AI solutions. A live call will follow the announcement at 8:30 a.m. ET.
1 min readWall Street analysts issued upgrades, downgrades, and initiations for several companies. Notable upgrades include Marvell (MRVL) to Buy with a $350 target and NetApp (NTAP) to Outperform with a $300 target. Downgrades include AppFolio (APPF) to Neutral with a $220 target. Initiations include Abbott Laboratories (ABT) with an Overweight rating and $120 target. Major indices closed at record highs, with the S&P 500 at 7,818 and Nasdaq at 27,599.
3 min readPhilips, GE HealthCare, and Siemens Healthineers face lawsuits from MR Access over alleged MRI patent infringements. The patents cover technology for improving MRI scan quality. MR Access, founded by MRI experts, seeks to license its patented technology.
2 min readNeedham maintained a Buy rating on GE HealthCare Techs with a $93 price target, implying 44.7% upside. The firm cited the $945M acquisition of Sofie Biosciences for growth and margin expansion, and expects mid-single digit revenue growth and high-single digit EPS growth.
1 min readEvercore ISI lowered its price target for GE Healthcare Technologies from $84 to $83, while maintaining an Outperform rating. The stock is currently trading at $64.32, reflecting a 0.05% gain over 5 days and a 4.55% decline over 1 year.
1 min readGE HealthCare (GEHC) will acquire Sofie Biosciences from Trilantic North America for $945M in cash. Sofie produces radioactive substances for medical imaging. The deal is expected to close in 2024, subject to regulatory approvals and customary closing conditions.
1 min readGE HealthCare has agreed to acquire SOFIE Biosciences, gaining U.S. rights to Phase III imaging agent FAPI-74. The deal expands GE HealthCare's footprint in the U.S. radiopharmaceutical market, enhancing access to PET radiopharmaceuticals. SOFIE operates 15 sites and is expected to grow in the low double digits. GE HealthCare anticipates the transaction will be accretive to revenue and earnings.
2 min readGE HealthCare Technologies (GEHC) supplied its MR31 deep learning MRI platform to AsiaMedic in the ASEAN region. This marks the first clinical MRI use of the MR31 system in ASEAN. The MR31 platform is designed to improve MRI scan quality and expand imaging options. GE HealthCare has a market value of about $29.5 billion and focuses on imaging hardware and digital tools.
2 min readGE HealthCare and Mass General Brigham are collaborating to develop a generative AI tool for radiation therapy. The tool aims to streamline treatment planning by integrating structured and unstructured data, potentially improving efficiency and personalization. GE HealthCare's Intelligent Radiation Therapy (iRT) software is the foundation for this research, which could expand its capabilities.
2 min readGE HealthCare appointed Rodolphe Katra as its new Global Chief AI Officer, aiming to expand AI use in devices, software, and healthcare data. Katra joins from Medtronic and will report to Taha Kass-Hout. GE HealthCare has 134 FDA-authorized AI-enabled medical devices, the most in the industry, according to CEO Peter Arduini.
2 min read
